Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.36
+0.17005.33%
Pre-market: 3.600.2400+7.14%07:21 EDT
Volume:3.94M
Turnover:12.61M
Market Cap:321.22M
PE:-2.79
High:3.37
Open:3.14
Low:3.06
Close:3.19
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:3.73
T/O Rate:4.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:1.06
PE(LYR):-0.85

Loading ...

Myriad Genetics Q1 revenue growth misses estimates

Reuters
·
May 06

Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate

Benzinga Earnings
·
May 06

BRIEF-Myriad Genetics Q1 EPS USD -0.36

Reuters
·
May 06

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

GlobeNewswire
·
May 06

Myriad Genetics Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 02

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

GlobeNewswire
·
Apr 30

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

GlobeNewswire
·
Apr 29

Myriad reports new MONITOR-Breast trial results for Precise MRD at AACR 2026

Reuters
·
Apr 16

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

GlobeNewswire
·
Apr 16

Myriad Genetics announces annual shareholder meeting webcast

Reuters
·
Apr 15

Japan health ministry approves Myriad MyChoice test as Lynparza companion for prostate cancer

Reuters
·
Apr 14

Myriad says Precise MRD ovarian cancer test predicts recurrence risk after adjuvant therapy

Reuters
·
Apr 09

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

GlobeNewswire
·
Apr 09

FDA approves Myriad MyChoice CDx as Zejula companion diagnostic for advanced ovarian cancer

Reuters
·
Mar 18

Myriad Genetics Receives FDA Approval of the Mychoice Cdx Test as the Companion Diagnostic for Zejula (Niraparib) for Patients With Ovarian Cancer

THOMSON REUTERS
·
Mar 18

Veracyte Appoints Kevin Haas as Chief Development and Technology Officer

MT Newswires Live
·
Mar 17

Veracyte appoints Kevin Haas as chief development and technology officer

Reuters
·
Mar 17